

## ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

## 宜明昂科生物醫藥技術(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代號: 1541)

20 February 2024

Dear registered shareholder(s),

## **Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <a href="www.immuneonco.com">www.immuneonco.com</a> and the HKEXnews website at <a href="www.hkexnews.hk">www.hkexnews.hk</a> in place of printed copies (the "Website Version"). A notice of publication of the Website Version of Corporate Communications, in both English and Chinese, will be sent by the Company to its shareholders by email or by post (only if the Company does not possess the functional email address of the shareholder) on the publication date of the Corporate Communications.

To ensure timely receipt of all future Corporate Communications, the Company recommends you provide your email address by scanning the QR code printed on the reply form enclosed (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company at Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai PRC.

If the Company does not receive your functional email address in your reply, until such time that the functional email address is provided to the Company, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications by email; and (ii) need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications.

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Company, Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai PRC or send an email to ir@immuneonco.com specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Company at 86-021-38016387 during business hours from 9:00 a.m. to 5:30 p.m. (Hong Kong time), Mondays to Fridays, excluding public holidays in Hong Kong and Mainland China.

Yours faithfully, By order of the Board ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Tian Wenzhi Chairman

各位登記股東:

## 以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則 (「上市規則」)第2.07條,宜明昂科生物醫藥技術(上海)股份有限公司(「公司」)謹此通知 閣下,公司已採用以電子方式發布公司通訊(「公司通訊」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用); (c)會議通知; (d)上市文件; (e)通函和 (f)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.immunconco.com 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本(「網站版本」)。本公司將於公司通訊刊發日期通過電子郵件方式或郵寄方式(僅在本公司沒有獲取股東有效的電子郵箱地址時)向股東發送公司通訊網站版本的登載通知,該通知將同時提供英文和中文版本。

為了確保及時收到所有未來的公司通訊,公司建議閣下透過掃描所附回條上列印的二維碼來提供閣下的電子郵件地址。 或者,閣下可以簽署回條並交回公司, 地址為上海浦東新區張衡路 1000 弄 15 號樓。

如果公司沒有從閣下回復收到閣下的有效電子郵件地址,直至公司收到閣下有效的電子郵件地址前,閣下將(i)無法收到任何有關發佈公司通訊的通知;及(ii)需要主動查看公司網站和披露易網站以留意公司通訊的發佈。

若 閣下希望收取公司通訊之印刷版,請填妥本函背頁之回條並交回公司,地址為上海浦東新區張衡路 1000 弄 15 號樓或發送電子郵件至 ir@immuneonco.com,並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意,收取日後公司通訊印刷版之指示由收悉閣下指示當日起計一年內有效,此後將過期。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港及中國大陸公眾假期除外)上午 9 時正至下午 5:30 時(香港時間) 其間致電公司 86-021-38016387 查詢。

> 承董事會命 宜明昂科生物醫藥技術(上海)股份有限公司 田文志 董事長 **謹**啟

		•
-	_	_

REPLY	<b>FORM</b>	回條
-------	-------------	----

To: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

(The Company)

Unit 15, 1000 Zhangheng Road

China (Shanghai) Pilot Free Trade Zone

Pudong New Area

Shanghai PRC 201203

(Please <u>choose ONLY ONE</u> of the options below) (請從以下選項中**只選擇其中一項**)

宜明昂科生物醫藥技術 (上海) 股份有限公司

中國上海浦東新區張衡路 1000 弄 15 號, 201203

Date:

日期:

(公司)

Personalized QR Code 專屬二維碼

Option 1: Provide your email address for receipt of future Corporate Communications\* of

the Company via electronic dissemination by scanning your personalized QR code

選項1:

掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式

發佈的未來公司通訊\*

或

You are **NOT required** to return this Reply Form if you choose Option 1.

如選擇了選項1, 閣下無須交回本回條

選項 2: 本人/吾等現以書面提供本人/吾等之電子郵件地址・以確保收到以下上市公司(「公司」)通過電子方式發佈的未來公司通訊。 可  Name of Securities holder(s) 證券持有人姓名:  Name of the listed company 上市公司名稱:  ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  宜明局科生物醫藥技術(上海)股份有限公司  Email address 電郵地址: (Notes 3 / 附註 3)	Option 2: I/we hereby provide my/our email address in writi "Company") via electronic dissemination.  OR	ing for receipt of future Corporate Communications* of the following listed company (the
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. <b>宜明昂科生物醫藥技術(上海)股份</b> 有限公司		·以確保收到以下上市公司(「公司」)通過電子方式發佈的未來公司通訊 <sup>。</sup>
Email address 電郵地址: (Notes 3 / 附註 3)	Name of Securities holder(s) 證券持有人姓名:	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
	Email address 電郵地址: (Notes 3 / 附註 3)	

Option 3:	I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "✓" in the below box if applicable)	
選項3:	<b>本人/吾等現要求收取公司通訊<sup>*</sup>印刷版</b> (如適用·請在以下方格內劃上「✓」號)	
		(Notes

receive future Corporate Communications\* in printed copy and noted that this instruction 山東京 Land Corporate Communications" in printed copy and noted that this instruction is very 他取未來公司通訊 的印刷本,並已知悉本指示由收取指示日期起計一年內有效。 (附註 5)

Signature(s): (Notes 1) Contact number: 簽名:*(附註1)* 聯絡電話號碼:

- 4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

  如 関下透過二線器 電影 回線及/減退地方式提供多於一個的電子器件地址、只有 関下最後提供的電子器件地址將會被用於登記。

  5. If you mark "~" in the box in Option 3, no email address will be received and only Corporate Communications, in printed form will be received.

  如 関下在境場3方括内動上 (\*)、蒙:將不會有電子器件地址被登記・只有公司遊訊\*的印刷版會被收取。

  6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.

  湯免存装:在本国输入的任何部外指示。公司將不予衛星。

- Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meetins, circular and proxy form. 條序另有註明:公司總訊/指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件,其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明